Lilly IL-17 inhibitor Taltz (ixekizumab) two clinical trials reach primary and secondary endpoint

today, Eli Lilly(http://announced that its IL-17 inhibitor Taltz (ixekizumab) has reached its primary and all critical secondaryin two clinicaltrials (http://treating patients with active psoriasis arthritis (PsA) and non-radioactive axial spinal arthritis (nr-axSpA)Lilly's monoclonal antibody, Taltz, selectively binds to leukocyte interleukin 17A (IL-17A) and inhibits its interaction with IL-17 receptorsIL-17A is a naturally occurring cytokine that participates in normal inflammatory and immune responsesBy inhibiting the IL-17 receptor-mediated signaling pathway, Taltz can inhibit the release of pro-inflammatory cytokines and chemokines, thereby reducing the symptoms of inflammatory diseasesPreviously, Taltz has been approved for the treatment of active PsA, active spinal itisen (AS), and moderate to severe plaque psoriasis patients suitable for systemic or phototherapyIn a Phase 3b/4 clinical trial called SPIRIT-H2H, patients with active psoriasis arthritis who had not been treated with a biologic spree were randomly assigned to treatment with Taltz or the common therapy adalimumab, and patients were treated with traditional anti-rheumaticdrug(http://(DMARDs)The results showed that after 52 weeks of treatment, the proportion of patients in the Taltz treatment group who achieved a 50% reduction in disease activity (ACR50) and complete removal of skin symptoms (PASI 100) was 39%, compared with 26% in the active control groupIn this Phase 3 clinical trial called COAST-X, nr-axSpA patients who have not been treated with the biologicanti-rheumatic drug (bDMARD) were treated with Taltz or placeboThe trial data showed that after 52 weeks of treatment, the proportion of patients in the treatment group who reached 40 (ASAS40) was 30 percent (treated every 4 weeks) and 31 percent (treated every 2 weeks), respectively, compared with 13 percent in the placebo group